Evidence map›Paper›PMID 39292401›Full record

ArticleAnnals of surgical oncology2025

Mainstream Germline Genetic Testing with Expanded Eligibility for Early Breast Cancer Patients in a Large Integrated Health System.

Veronica Shim, Audrey Karlea, Leslie Manace Brenman, Jamila Gul, Elizabeth Hoodfar, Tracy D Chan, Poline C Engeman, Vanessa M Sheldon, Deirdre M Thorne-Hadfield, Patience Odele and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Mainstreaming genetic testing in community oncology settings.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Veronica ShimDepartment of Surgery, Kaiser Permanente Oakland Medical Center, Oakland, CA, USA. veronica.shim@kp.org.
Audrey KarleaDepartment of Genetics, Oakland, Kaiser Permanente, Oakland, USA.
Leslie Manace BrenmanDepartment of Genetics, Oakland, Kaiser Permanente, Oakland, USA.
Jamila GulDivision of Research, Oakland, Kaiser Permanente, Oakland, USA.
Elizabeth HoodfarDepartment of Genetics, Sacramento, Kaiser Permanente, Sacramento, USA.
Tracy D ChanDepartment of Surgery, Kaiser Permanente Oakland Medical Center, Oakland, CA, USA.
Poline C EngemanDepartment of Surgery, South Sacramento, Kaiser Permanente, Sacramento, USA.
Vanessa M SheldonDepartment of Surgery, Central Valley, Kaiser Permanente, Modesto, USA.
Deirdre M Thorne-HadfieldDepartment of Radiology, San Rafael, Kaiser Permanente, San Rafael, USA.
Patience OdeleDepartment of Surgery, San Rafael, Kaiser Permanente, San Rafael, USA.
Brooke VuongDepartment of Surgery, South Sacramento, Kaiser Permanente, Sacramento, USA.
Jennifer McEvoyDepartment of Surgery, Central Valley, Kaiser Permanente, Modesto, USA.
C K ChangDepartment of Surgery, Kaiser Permanente Oakland Medical Center, Oakland, CA, USA.
Dinesh KotakDepartment of Medical Oncology, San Rafael, Kaiser Permanente, San Rafael, USA.
Laurel A HabelDivision of Research, Oakland, Kaiser Permanente, Oakland, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study evaluated a new mainstream genetic testing pathway for hereditary cancer, with expanded eligibility for early-stage breast cancer patients.

methodsThe study compared multigene panel (62 genes) germline testing uptake and results for breast cancer patients at 4 pilot sites (n = 502 patients) and 10 non-pilot sites (n = 1792 patients) within Kaiser Permanente Northern California from December 2020, to June 2021. At the pilot sites, breast care coordinators (BCCs) offered and consented patients for testing, with eligibility expanded to include all patients age 65 years or younger. At the non-pilot sites, eligible patients were referred to genetics for pre-test counseling, ordering, and follow-up evaluation with the standard guideline that included all patients age 45 years or younger.

resultsDemographic and disease characteristics were similar at the pilot and non-pilot sites. At the pilot verses non-pilot sites, a higher percentage of patients was tested overall (61.6% vs 31.7%) and across all age groups. The median time from breast biopsy to test result also was reduced (22 vs 33 days, respectively). A higher percentage of patients at the pilot sites was identified as having a pathogenic/likely pathogenic variant (PV/LPV) in a breast cancer-related gene (3.6% vs 1.6%). Although the percentage of total patients tested was nearly twofold higher at the pilot sites than at the non-pilot sites, the percentage of total patients seen by genetics was estimated to be similar (33.7% vs 31.7%).

conclusionMainstream genetic testing of breast cancer patients facilitated by BCCs makes it feasible for a large health care system to expand germline genetic testing to early breast cancer patients age 65 years or younger.

Indexed as

Breast NeoplasmsDelivery of Health Care, IntegratedGenetic TestingGerm-Line MutationAdultAgedBiomarkers, TumorCaliforniaFemaleFollow-Up StudiesGenetic CounselingGenetic Predisposition to DiseaseHumansMiddle AgedPilot ProjectsPrognosisBiomarkers, TumorBreast cancerBreast cancer-related geneMainstream germline genetic testingMultigene panelPathogenic/likely pathogenic variant

Identifiers

PMID39292401
PMCPMC11659365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.